Clair Nelson Hayes
Overview
Explore the profile of Clair Nelson Hayes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagaoki Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, et al.
Therap Adv Gastroenterol
. 2025 Mar;
18:17562848251324094.
PMID: 40078327
Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving...
2.
Kosaka M, Fujino H, Tsuge M, Yamaoka K, Fujii Y, Uchikawa S, et al.
J Gastroenterol
. 2025 Jan;
PMID: 39841247
Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the...
3.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, et al.
J Gastroenterol
. 2024 Dec;
60(3):328-339.
PMID: 39652104
Background: This study aims to identify biomarkers for treatment response of atezolizumab plus bevacizumab (Atezo+Bev) in patients with hepatocellular carcinoma (HCC). Methods: 96 patients who received Atezo+Bev or lenvatinib as...
4.
Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H, et al.
Viruses
. 2024 Nov;
16(11).
PMID: 39599858
Cross-sectional analyses using liver tissue from chronic hepatitis B patients make it difficult to exclude the influence of host immune responses. In this study, we performed next-generation sequencing using the...
5.
Tanaka A, Kawaoka T, Uchikawa S, Fujino H, Ono A, Murakami E, et al.
Clin J Gastroenterol
. 2024 Oct;
18(1):107-113.
PMID: 39446307
A 58-year-old man visited an orthopedic clinic complaining of pain in his right lower back and numbness in his lower limbs for one month. Imaging tests revealed a tumorous lesion...
6.
Shirane Y, Fujii Y, Ono A, Nakahara H, Hayes C, Miura R, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611007
The therapeutic benefits of the immunotherapeutic combination of atezolizumab and bevacizumab (Atez/Bev) in hepatocellular carcinoma (HCC) vary. Therapeutic biomarkers might help improve outcomes for HCC patients receiving Atez/Bev therapy. The...
7.
Tamura Y, Ono A, Nakahara H, Hayes C, Fujii Y, Zhang P, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686510
It has been reported that high intensity in the hepatobiliary (HB) phase of Gd-EOB-DTPA-enhanced MRI (EOB-MRI) is associated with an immune-cold microenvironment in HCC. The aim of this study is...
8.
Uchida T, Teraoka Y, Imamura M, Abe-Chayama H, Makokha G, Hayes C, et al.
J Viral Hepat
. 2022 Dec;
30(3):262-272.
PMID: 36575861
Although human hepatocyte-transplanted immunodeficient mice support infection with hepatitis viruses, these mice fail to develop viral hepatitis due to the lack of an adaptive immune system. In this study, we...
9.
Zhang P, Ono A, Fujii Y, Hayes C, Tamura Y, Miura R, et al.
Int J Cancer
. 2022 Sep;
151(12):2278-2290.
PMID: 36054900
Recently, a distinct vascular pattern in hepatocellular carcinoma (HCC) called vessels encapsulating tumor-forming clusters (VETC) has received attention because of its association with poor prognosis. However, little is known about...
10.
Yoshikawa Y, Imamura M, Yamaoka K, Kosaka Y, Murakami E, Morio K, et al.
Clin J Gastroenterol
. 2020 Nov;
14(1):283-287.
PMID: 33200345
Immune checkpoint inhibitor (ICI) therapy has potent anti-cancer effects but is associated with immune-related adverse events (irAEs). We present a case who developed secondary sclerosing cholangitis following treatment with nivolumab...